Avanir, Novartis Enter $210M Agreement On Inflammation
Avanir Pharmaceuticals Inc. partnered its first preclinical program, doing so with Novartis AG to develop small-molecule drugs that target macrophage migration inhibitory factor.(BioWorld Today)
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.